• |
Compugen is the only company evaluating a potential synergistic triple blockade of PVRIG, TIGIT and PD-1 in the clinic, a comprehensive evaluation of the DNAM axis and a key differentiator in the TIGIT space
|
• |
Updated data from first in class anti-PVRIG, COM701 Phase 1 monotherapy and in combination with Opdivo®, presented at ASCO 2021 show durable responses and disease control in patients who exhausted all prior treatment options as well as preliminary pharmacodynamic biomarker data supporting COM701 potential immune mediated mechanism of action
|
• |
Strong execution with initiation of three clinical studies including Phase 1b cohort expansion of COM701 with Opdivo®, Phase 1 combination of COM902 and COM701, and Phase 1/2 triple combination cohort expansion of COM701 in combination with Opdivo® and Bristol Myers Squibb anti-TIGIT, BMS-986207
|
• |
Milestone rich 2021, including initial data from ongoing COM701 triple combination dose escalation study and COM902 monotherapy dose escalation study both on track for Q4 2021
|
• |
Presented updated data from the COM701 monotherapy and combination with Opdivo® (nivolumab) studies at the ASCO 2021 Annual Meeting including:
|
o |
Durable responses beyond one year, including one complete response, in tumor types typically unresponsive to checkpoint inhibitors
|
o |
Preliminary biomarker data reveal immune activation evidenced by a trend of increased proliferation of peripheral immune cells and IFNγ. IFNγ increased with increasing doses of COM701, suggesting the observed activity is likely derived from the combination treatment and not Opdivo® alone
|
o |
Preliminary anti-tumor activity in PD-L1 low, PVRL2 positive patients, with non-inflamed tumor microenvironment/immune desert phenotype
|
• |
Dosed the first patient in the Phase 1b cohort expansion study of COM701 in combination with Opdivo® in patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers
|
• |
Dosed the first patient in the Phase 1 dual combination study of COM902 and COM701 in patients with advanced malignancies, the first clinical study of dual blockade of TIGIT and PVRIG independent of anti-PD-1
|
• |
Dosed the first patient in the Phase 1/2 triple combination cohort expansion of COM701 with Opdivo® and Bristol Myers Squibb's anti-TIGIT antibody, BMS-986207
|
• |
Presented research at the Society for Immunotherapy of Cancer (SITC) Targets for Cancer Immunotherapy: A Deep Dive Seminar Series, supporting PVRIG as a novel and differentiated checkpoint in the DNAM axis
|
COMPUGEN LTD.
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
(U.S. dollars in thousands, except for share and per share amounts)
|
Three Months Ended
|
Six Months Ended,
| |||||||||||||||
June 30,
|
June 30,
| |||||||||||||||
2021
|
2020
|
2021
|
2020
| |||||||||||||
Unaudited
|
Unaudited
|
Unaudited
|
Unaudited
| |||||||||||||
Operating expenses
| ||||||||||||||||
Research and development expenses
|
6,797
|
4,447
|
14,123
|
9,159
| ||||||||||||
Marketing and business development expenses
|
241
|
204
|
465
|
414
| ||||||||||||
General and administrative expenses
|
2,659
|
2,131
|
5,373
|
4,607
| ||||||||||||
Total operating expenses
|
9,697
|
6,782
|
19,961
|
14,180
| ||||||||||||
Financial and other income, net
|
200
|
536
|
559
|
806
| ||||||||||||
Loss before taxes on income
|
(9,497
|
)
|
(6,246
|
)
|
(19,402
|
)
|
(13,374
|
)
| ||||||||
Taxes on income
|
-
|
-
|
-
|
-
| ||||||||||||
Net loss
|
(9,497
|
)
|
(6,246
|
)
|
(19,402
|
)
|
(13,374
|
)
| ||||||||
Basic and diluted net loss per ordinary share
|
(0.11
|
)
|
(0.08
|
)
|
(0.23
|
)
|
(0.18
|
)
| ||||||||
Weighted average number of ordinary shares used in computing basic and diluted net loss per share
|
83,799,634
|
81,273,240
|
83,739,983
|
75,774,881
|
COMPUGEN LTD.
|
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
|
(U.S. dollars, in thousands)
|
June 30,
|
December 31,
| |||||||
2021
|
2020
| |||||||
Unaudited
| ||||||||
ASSETS
| ||||||||
Current assets
| ||||||||
Cash, cash equivalents, short-term bank deposits and restricted cash
|
111,092
|
124,432
| ||||||
Trade receivables
|
2,000
| |||||||
Other accounts receivable and prepaid expenses
|
2,662
|
2,658
| ||||||
Total current assets
|
113,754
|
129,090
| ||||||
Non-current assets
| ||||||||
Long-term prepaid expenses
|
1,906
|
1,880
| ||||||
Severance pay fund
|
3,017
|
2,863
| ||||||
Operating lease right to use asset
|
2,415
|
2,772
| ||||||
Property and equipment, net
|
1,724
|
1,711
| ||||||
Total non-current assets
|
9,062
|
9,226
| ||||||
Total assets
|
122,816
|
138,316
| ||||||
LIABILITIES AND SHAREHOLDERS EQUITY
| ||||||||
Current liabilities
| ||||||||
Other accounts payable, accrued expenses and trade payables
|
10,484
|
9,216
| ||||||
Current maturity of operating lease liability
|
706
|
639
| ||||||
Short-term deferred participation in R&D expenses
|
660
|
668
| ||||||
Total current liabilities
|
11,850
|
10,523
| ||||||
Non-current liabilities
| ||||||||
Long-term deferred participation in R&D expenses
|
1,798
|
1,968
| ||||||
Long-term operating lease liability
|
2,141
|
2,527
| ||||||
Accrued severance pay
|
3,606
|
3,516
| ||||||
Total non-current liabilities
|
7,545
|
8,011
| ||||||
Total shareholders' equity
|
103,421
|
119,782
| ||||||
Total liabilities and shareholders' equity
|
122,816
|
138,316
|
Attachments
- Original document
- Permalink
Disclaimer
Compugen Ltd. published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 11:13:05 UTC.